Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [E200] to ErbB4 / HER4
- Suitable for: WB, IP
- Reacts with: Mouse, Rat, Human
Product nameAnti-ErbB4 / HER4 antibody [E200]
See all ErbB4 / HER4 primary antibodies
DescriptionRabbit monoclonal [E200] to ErbB4 / HER4
This antibody is specific to ErbB4 / HER4. It does not cross react with other EGF receptor family members.
Tested applicationsSuitable for: WB, IPmore details
Unsuitable for: ICC or IHC
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human ErbB4/ HER4 (C terminal). The exact sequence is proprietary.
- WB: MCF7 and T47D cell lysate. IP: HEK-293 cell lysate.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 49% PBS, 50% Glycerol, 0.05% BSA
Concentration information loading...
Our Abpromise guarantee covers the use of ab32375 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 147 kDa.|
FunctionSpecifically binds and is activated by neuregulins, NRG-2, NRG-3, heparin-binding EGF-like growth factor, betacellulin and NTAK. Interaction with these factors induces cell differentiation. Not activated by EGF, TGF-A, and amphiregulin. The C-terminal fragment (CTF) of isoform JMA-A CYT-2 (containing E4ICD2) can stimulate transcription in the presence of YAP1. ERBB4 intracellular domain is involved in the regulation of cell growth. Conflicting reports are likely due at least in part to the opposing effects of the isoform-specific and nuclear-translocated ERBB4 intracellular domains (E4ICD1 and E4ICD2). Overexpression studies in epithelium show growth inhibition using E4ICD1 and increased proliferation using E4ICD2. E4ICD2 has greater in vitro kinase activity than E4ICD1. The kinase activity is required for the nuclear translocation of E4ICD2.
Tissue specificityExpressed at highest levels in brain, heart, kidney, in addition to skeletal muscle, parathyroid, cerebellum, pituitary, spleen, testis and breast. Lower levels in thymus, lung, salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are expressed in cerebellum, but only the isoform JM-B is expressed in the heart.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
Contains 1 protein kinase domain.
modificationsIsoform JM-A CYT-1 and isoform JM-A CYT-2 but not isoform JM-B CYT-1 and isoform JM-B CYT-2 are processed by ADAM17. Proteolytic processing in response to ligand or 12-O-tetradecanoylphorbol-13-acetate stimulation results in the production of 120 kDa soluble receptor forms and intermediate membrane-anchored 80 kDa fragments (m80HER4), which are further processed by a presenilin-dependent gamma-secretase to release the respective cytoplasmic intracellular domain E4ICD (either E4ICD1/s80Cyt1 or E4ICD2/s80Cyt2). Membrane-anchored 80 kDa fragments of the processed isoform JM-A CYT-1 are more readily degraded by the proteasome than fragments of isoform JM-A CYT-2 suggesting a prevalence of E4ICD2 over E4ICD1.
Ligand-binding increases phosphorylation on tyrosine residues. Isoform JM-A CYT-2 is constitutively phosphorylated on tyrosine residues in a ligand-independent manner. E4ICD2 but not E4ICD1 is phosphorylated on tyrosine residues.
Ubiquitinated. The ERBB4 intracellular domain is ubiquitinated and targeted to proteosomal degradation during mitosis mediated by the APC/C complex. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is ubiquitinated, and this involves NEDD4.
Cellular localizationMembrane and Nucleus. Following proteolytical processing E4ICD (E4ICD1 or E4ICD2 generated from the respective isoforms) is translocated to the nucleus. Significantly more E4ICD2 than E4ICD1 is found in the nucleus. E4ICD2 colocalizes with YAP1 in the nucleus.
- Information by UniProt
- 4ICD antibody
- ALS19 antibody
- Avian erythroblastic leukemia viral oncogene homolog 4 antibody
All lanes : Anti-ErbB4 / HER4 antibody [E200] (ab32375) at 1.09 µg/ml
Lane 1 : MCF7 (Human breast adenocarcinoma epithelial cell)
Lane 2 : T47D (Human ductal breast epithelial tumor epithelial cell)
Lane 3 : T47D (Human ductal breast epithelial tumor epithelial cell) low exposure image of lane 2
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 0.05 µg/ml
Predicted band size: 147 kDa
Anti-ErbB4 / HER4 antibody [E200] (ab32375) at 1/4000 dilution + MCF7 cell lysate
Predicted band size: 147 kDa
Observed band size: 185 kDa why is the actual band size different from the predicted?
Lane 1 (input): HEK-293 (human embryonic kidney epithelial cell) whole cell lysate, 10μg
Lane 2 (+): HEK-293 whole cell lysate
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab32375 in HEK-293 whole cell lysate
Ab32375 Immunoprecipitating ErbB 4 in HEK-293 whole cell lysate. Capture antibody was used at a 1:50 dilution (2μg in 0.35mg lysates). For western blotting, primary antibody used as ab32375 at 1:500 dilution. Ab131366 VeriBlot for IP Detection Reagent (HRP) was used for detection at 1:1000 dilution. The lower band at around 75kDa should be proteolysis fragment based on the literature. (PMID: 9362517)
Blocking and diluting buffer: 5% NFDM/TBST
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab32375 has been referenced in 16 publications.
- Wintgens JP et al. Monitoring activities of receptor tyrosine kinases using a universal adapter in genetically encoded split TEV assays. Cell Mol Life Sci 76:1185-1199 (2019). PubMed: 30623207
- Yan T et al. Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. Nat Commun 10:1670 (2019). PubMed: 30975989
- Ni H et al. ErbB4 acts as a suppressor in colitis and its associated carcinoma by negatively regulating cholesterol metabolism. Carcinogenesis N/A:N/A (2018). PubMed: 30452622
- Wang H et al. HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1. Biochim Biophys Acta 1864:1839-1849 (2018). PubMed: 29524631
- Geng HY et al. Erbb4 Deletion from Medium Spiny Neurons of the Nucleus Accumbens Core Induces Schizophrenia-Like Behaviors via Elevated GABAA Receptor a1 Subunit Expression. J Neurosci 37:7450-7464 (2017). PubMed: 28667174